Molecular Basis of Partial Agonism at the Neurotransmitter α2A-Adrenergic Receptor and Gi-protein Heterotrimer*

To characterize the mechanism by which heterotrimeric G-proteins interpret the signals coming from various neurotransmitters of diverse efficacies (agonists and partial agonists) acting on α2A-adrenergic receptors, we used a fluorescent resonance energy transfer-based approach to study the effects of these partial agonists on the activation process of both the α2A-adrenergic receptor and its cognate Gi-protein. We show that ligands of different efficacies switch the receptor into distinct conformational states, which in turn set the speed and extent of the Gi-protein signaling. Thus, in cells the efficacy by which a receptor responds to diverse ligands is caused by the ability of the G-protein to differentiate between distinct receptor conformations. The data provide a new key characteristic underlying the mechanism of partial agonism at G-protein-coupled receptors.

[1]  R Seifert,et al.  Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. , 1999, Molecular pharmacology.

[2]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[3]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[4]  M. Lohse,et al.  Molecular basis of inverse agonism in a G protein–coupled receptor , 2005, Nature chemical biology.

[5]  T. Kenakin Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.

[6]  Martin J. Lohse,et al.  Novel Single Chain cAMP Sensors for Receptor-induced Signal Propagation*♦ , 2004, Journal of Biological Chemistry.

[7]  Stefan Offermanns,et al.  Mammalian G proteins and their cell type specific functions. , 2005, Physiological reviews.

[8]  T. Kenakin,et al.  The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. , 2000, Molecular pharmacology.

[9]  Mark H Ellisman,et al.  A FlAsH-based FRET approach to determine G protein–coupled receptor activation in living cells , 2005, Nature Methods.

[10]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.

[11]  Terry Kenakin,et al.  Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.

[12]  P. Morgan,et al.  The Cubic Ternary Complex ReceptorOccupancy Model I. Model Description , 1996 .

[13]  M. Lohse,et al.  Measurement of the millisecond activation switch of G protein–coupled receptors in living cells , 2003, Nature Biotechnology.

[14]  B. Kobilka,et al.  Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. , 2001, The Journal of pharmacology and experimental therapeutics.

[15]  M. Lohse,et al.  Gi protein activation in intact cells involves subunit rearrangement rather than dissociation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P Ghanouni,et al.  Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.

[17]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.